Compare · BNGO vs WAT
BNGO vs WAT
Side-by-side comparison of Bionano Genomics Inc. (BNGO) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNGO and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $40.72B, about 2765.9x BNGO ($14.7M).
- BNGO has been more active in the news (13 items in the past 4 weeks vs 6 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 5 for BNGO).
- Company
- Bionano Genomics Inc.
- Waters Corporation
- Price
- $1.25+2.46%
- $414.21+0.88%
- Market cap
- $14.7M
- $40.72B
- 1M return
- +14.68%
- -
- 1Y return
- -68.59%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- 1995
- News (4w)
- 13
- 6
- Recent ratings
- 5
- 25
Bionano Genomics Inc.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest BNGO
- Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Interim Chief Executive Luderer Albert bought $4,860 worth of shares (4,000 units at $1.22) (SEC Form 4)
- SEC Form 10-Q filed by Bionano Genomics Inc.
- Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Bionano Reports Second Quarter 2026 Results and Provides a Business Update
- SEC Form 4 filed by Principal Accounting Officer Adamchak Mark
- SEC Form 4 filed by General Counsel Dixon Jonathan V.
- SEC Form 4 filed by Chief Operating Officer Oldakowski Mark
- SEC Form 4 filed by Chief Scientific Officer Hastie Alex Reid
- SEC Form 3 filed by new insider Oldakowski Mark
Latest WAT
- SEC Form 8-K filed by Waters Corporation
- SEC Form 10-Q filed by Waters Corporation
- Director Kuebler Christopher A sold $1,442,930 worth of shares (3,626 units at $397.94) and exercised 3,626 shares at a strike of $136.43 (SEC Form 4)
- Waters upgraded by TD Cowen with a new price target
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
- Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)